Ge Long Hui A P P·2025-08-22 07:43Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyuan Biochemical Pharmaceutical Co., Ltd., received drug registration certificates from the Philippines Food and Drug Administration for the approval of Oxytocin Injection and Acetate Octreotide Injection for market launch [1] Group 1: Product Approvals - Oxytocin Injection is primarily used for induction of labor, postpartum hemorrhage due to uterine atony, and assessing placental reserve function [1] - Acetate Octreotide Injection is mainly used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, preventing postoperative complications from pancreatic surgery, and managing esophageal variceal bleeding [1]